Oramed Pharmaceuticals (NASDAQ:ORMP) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02, Zacks reports.

Oramed Pharmaceuticals Price Performance

Shares of ORMP stock traded down $0.03 on Friday, hitting $3.29. The stock had a trading volume of 38,932 shares, compared to its average volume of 208,699. The business has a 50 day moving average of $3.41 and a 200 day moving average of $2.91. The stock has a market cap of $130.87 million, a price-to-earnings ratio of 2.61 and a beta of 1.31. Oramed Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $3.76.

Oramed Pharmaceuticals Dividend Announcement

The company also recently announced a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were paid a $0.25 dividend. The ex-dividend date was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio is presently 19.84%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its position in Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 17,510 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Oramed Pharmaceuticals by 4.4% during the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after buying an additional 6,261 shares in the last quarter. HRT Financial LP purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth approximately $131,000. Marshall Wace LLP purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth approximately $738,000. Finally, Squarepoint Ops LLC grew its holdings in shares of Oramed Pharmaceuticals by 95.1% in the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 28,406 shares in the last quarter. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oramed Pharmaceuticals has a consensus rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.